UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
Commission file number

(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code:
(
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(b) Ms. Stueland Departure
On November 15, 2026, GeneDx Holdings Corp. (“GeneDx”) and Katherine Stueland agreed that Ms. Stueland will step down from her role as Chief Executive Officer (“CEO”) of GeneDx and resign from the Board of Directors (the “Board”) of GeneDx, effective as of the first date of employment of Everett Cunningham, expected to be on or before December 15, 2026 (the “Transition Date”). Ms. Stueland’s departure is not related to any disagreement on any matter relating to GeneDx’s operations, policies or practices. Ms. Stueland has agreed to remain employed by GeneDx as Executive Advisor, reporting to the Board, through January 31, 2027 (the “Exit Date”). In connection with Ms. Stueland’s departure, GeneDx and Ms. Stueland entered into a transition agreement that is substantively consistent with the terms of Ms. Stueland’s employment agreement with GeneDx, dated as of January 14, 2022, as amended and restated on April 29, 2022 (the “Stueland Employment Agreement”), that would have applied in the event of a termination without Cause outside of a Change in Control (each as defined in the Stueland Employment Agreement), except that in lieu of any salary severance, Ms. Stueland will receive accelerated vesting of her restricted stock units that would otherwise have vested in March 2027, effective as of the Exit Date and subject to her execution and non-revocation of a release of claims. Ms. Stueland will also continue to receive her current compensation and vest in her outstanding equity awards through the Exit Date.
(c) New CEO Appointment
Additionally, on November 15, 2026, the Board appointed Everett Cunningham as CEO of GeneDx, effective as of the Transition Date. The Board also appointed Mr. Cunningham as a Class II director, effective as of the Transition Date, to serve for a term expiring at GeneDx’s 2029 annual meeting of stockholders.
Mr. Cunningham served as President and Chief Executive Officer and a director of Quanterix Corporation from January 2026 to November 2026. Before Quanterix, he was Chief Commercial Officer of Illumina, Inc. from June 2024 to January 2026. From 2021 to 2024, he served as Chief Commercial Officer of Exact Sciences Corporation. Previously, he was President and Chief Executive Officer of GE Healthcare’s U.S. & Canada region from 2019 to 2021 and Senior Vice President, Commercial at Quest Diagnostics from 2012 to 2019. From 1991 to 2012, he held a series of senior leadership roles at Pfizer Inc., including Regional President, Established Products for Asia Pacific, and Vice President of Sales for U.S. Pharmaceuticals. Mr. Cunningham serves on the board of directors of Arvinas, Inc. (Nasdaq: ARVN). He holds a bachelor’s degree in economics from Northwestern University.
There are no arrangements or understandings between Mr. Cunningham and any other person pursuant to which he was selected as CEO, no family relationships between Mr. Cunningham and any director or executive officer of GeneDx, and no transactions in which Mr. Cunningham has an interest requiring disclosure under Item 404(a) of Regulation S-K.
In connection with his appointment as CEO, Mr. Cunningham will be eligible to receive an initial annual base salary of $750,000 and a target annual cash bonus equal to 100% of his base salary (with the actual bonus ranging from 0% to 150% of target) beginning in GeneDx’s fiscal year 2027. Mr. Cunningham will also receive a sign-on cash bonus of $1,050,000, which is subject to repayment if his employment terminates under certain circumstances prior to the first anniversary of the Transition Date, as well as relocation and legal fee reimbursement. In addition, within thirty (30) days following the Transition Date (the “Grant Date”), Mr. Cunningham will be granted a restricted stock unit award equal to $10.0 million of GeneDx’s Class A common stock, based on the 60-trading-day trailing average closing price of GeneDx’s Class A common stock ending on the trading day immediately prior to the Grant Date (the “60-Day Average”) (the “Cunningham RSU”). The Cunningham RSU will vest over four (4) years in equal annual installments, subject to Mr. Cunningham’s continued service on each time-based vesting date. On the Grant Date, Mr. Cunningham will also be granted a performance-based restricted stock unit award covering a number of shares of GeneDx’s Class A common stock equal to $10.0 million divided by the 60-Day Average (the “PRSU Award”), which will be divided into four (4) equal tranches (each, a “Tranche”), each of which will require achievement of a stock price target (each, a “Price Hurdle”) during such Tranche’s specific performance period, the last of which ends on the fifth anniversary of the Grant Date, as well as Mr. Cunningham’s continued service on each time-based vesting date of the PRSU Award. Mr. Cunningham will also be granted, when GeneDx grants its 2027 annual refresh awards to its named executive officers, a performance-based restricted stock unit award with an approximate target value of $4,000,000, on the same terms as those granted to GeneDx’s other executive officers, subject to his continued service through the grant date.
In addition, Mr. Cunningham will enter into an employment agreement with GeneDx (the “Cunningham Employment Agreement”), a copy of which will be filed with GeneDx’s Annual Report on Form 10-K for the year ending December 31, 2026.
Pursuant to the Cunningham Employment Agreement, if Mr. Cunningham’s employment is terminated without Cause or he resigns for Good Reason other than during a Change in Control Period (each as defined in the Cunningham Employment Agreement), and Mr. Cunningham delivers a release of claims in favor of GeneDx, he will be entitled to receive: (i) 24 months of his base salary; (ii) reimbursement of premiums for COBRA continuation coverage for up to 24 months; and (iii) full acceleration of the Cunningham RSU.
Likewise, pursuant to the Cunningham Employment Agreement, in the event that Mr. Cunningham’s employment is terminated without Cause or he resigns for Good Reason during a Change in Control Period, and Mr. Cunningham delivers a release of claims in favor of GeneDx, he will be entitled to receive: (i) 24 months of his base salary; (ii) a lump sum equal to two times his target annual bonus; (iii) full acceleration of all then-outstanding equity awards to the extent then subject solely to time-based vesting conditions (including any Tranches of the PRSU Award for which the Price Hurdle has been achieved); and (iv) reimbursement of premiums for COBRA continuation coverage for up to 24 months.
Mr. Cunningham will enter into GeneDx’s standard form of indemnification agreement, filed as Exhibit 10.4 to GeneDx’s Current Report on Form 8-K (File No. 001-39482) filed with the Securities and Exchange Commission on July 28, 2021.
Item 7.01 Regulation FD Disclosure
A copy of the press release announcing Mr. Cunningham’s appointment and the end of Ms. Stueland’s service is attached hereto as Exhibit 99.1. The information in the press release attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
Exhibit Number |
Description | |
| 99.1 | Press Release dated November 18, 2026 | |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GeneDx Holdings Corp. | ||
| Date: November 18, 2026 | By: | /s/ Heidi Chen |
| Name: | Heidi Chen | |
| Title: | Chief Legal Officer | |